Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Overview
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Celltrion Inc
ChemoCentryx Inc
Generium
GlaxoSmithKline Plc
Humanigen Inc
iBio Inc
InflaRx NV
Insmed Inc
Nichi-Iko Pharmaceutical Co Ltd
Pharmapraxis
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HGEN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INS-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Dormant Projects
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Discontinued Products
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Figure 1: Number of Products under Development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Table 1: Number of Products under Development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 9: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Celltrion Inc, H2 2019
Table 10: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by ChemoCentryx Inc, H2 2019
Table 11: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Generium, H2 2019
Table 12: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 13: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Humanigen Inc, H2 2019
Table 14: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by iBio Inc, H2 2019
Table 15: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by InflaRx NV, H2 2019
Table 16: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Insmed Inc, H2 2019
Table 17: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2019
Table 18: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Pharmapraxis, H2 2019
Table 19: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Dormant Projects, H2 2019
Table 20: Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Discontinued Products, H2 2019